All In Biotech

Drug Trial Radar · NCT06554795

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Sep 3, 2024

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
DualityBio Inc.Industry
Sponsor type
Industry
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors

Conditions

  • Solid Tumor, Adult

Interventions

  • DB-1419Drug

    Administered Injection of Vein (I.V.)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1/2a: Percentage of Participants with Adverse events (AE) serious AE (SAE)Time frame: Up to 90 days after last study treatment administration or before starting new anticancer treatment, whichever comes first
  2. Phase 1/2a: Percentage of Participants with serious AE (SAE)Time frame: Up to 90 days after last study treatment administration or before starting new anticancer treatment, whichever comes first
  3. Phase 1a: Maximum Tolerated Dose (MTD)Time frame: From first study treatment administration until the initiation of Phase1b/2a, approximately up to 12 months.
  4. Phase 1a: Recommended Phase 2 Dose (RP2D)Time frame: From first study treatment administration until the initiation of Phase 1b/2a, approximately up to 12 months.
  5. Phase 1b/2a: Objective Response Rate (ORR) determined by Investigator per RECIST v1.1Time frame: Up to disease progression or death or before starting new anticancer treatment or withdrawal from the trial, whichever comes first, approximately up to 12 months.

Locations

36 sites in 3 countries. Site status is shown where the registry gives one.

  • Site USA12-0

    Los Angeles, California · Recruiting

  • Site USA08-0

    Newport Beach, California · Recruiting

  • Site USA06-0

    Washington D.C., District of Columbia · Recruiting

  • Site USA02-0

    Florida City, Florida · Recruiting

  • Site USA11-0

    Chicago, Illinois · Recruiting

  • Site USA03

    Huntersville, North Carolina · Recruiting

  • Site USA05-0

    Philadelphia, Pennsylvania · Not yet recruiting

  • Site USA07-0

    Nashville, Tennessee · Recruiting

  • Site USA09-0

    West Valley City, Utah · Recruiting

  • AUS03-0

    North Ryde, New South Wales, Australia · Recruiting

  • AUS01-0

    Randwick, New South Wales, Australia · Recruiting

  • AUS02-0

    Nedlands, Washington, Australia · Recruiting

  • Site CHN24-0

    Hefei, Anhui, China · Not yet recruiting

  • Site CHN39-0

    Hefei, Anhui, China · Not yet recruiting

  • Site CHN28-0

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Site CHN13-0

    Jilin City, Changchun, China · Not yet recruiting

  • Site CHN16-0

    Chongqing, Chongqing Municipality, China · Recruiting

  • Site CHN20-0

    Fuzhou, Fujian, China · Recruiting

  • Site CHN32-0

    Nanning, Guangxi, China · Not yet recruiting

  • Site CHN08-0

    Harbin, Heilongjiang, China · Recruiting

  • Site CHN23-0

    Harbin, Heilongjiang, China · Not yet recruiting

  • Site CHN03-0

    Luoyang, Henan, China · Recruiting

  • Site CHN09-0

    Zhengzhou, Henan, China · Not yet recruiting

  • Site CHN25-0

    Zhengzhou, Henan, China · Not yet recruiting

  • Site CHN34-0

    Wuhan, Hubei, China · Recruiting

  • Site CHN21-0

    Changsha, Hunan, China · Recruiting

  • Site CHN31-0

    Shenyang, Liaoning, China · Not yet recruiting

  • Site CHN29-0

    Jinan, Shandong, China · Not yet recruiting

  • Site CHN26-0

    Linyi, Shandong, China · Recruiting

  • Site CHN01-0

    Shanghai, Shanghai Municipality, China · Recruiting

  • Site CHN15-0

    Shanghai, Shanghai Municipality, China · Recruiting

  • Site CHN18-0

    Chengdu, Sichuan, China · Recruiting

  • Site CHN38-0

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Site CHN19-0

    Kunming, Yunnan, China · Not yet recruiting

  • Site CHN17-0

    Hangzhou, Zhejiang, China · Not yet recruiting

  • Site CHN37-0

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.